QuantiFERON-TB supernatant-based biomarkers predicting active tuberculosis progression
Background: Despite the higher specificity and reliability of detecting latent tuberculosis (TB) infection, Mycobacterium tuberculosis-specific interferon (IFN)-γ release assays do not perform satisfactorily in predicting the risk of active TB (ATB) development. It is crucial to identify new biomark...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971225001389 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Despite the higher specificity and reliability of detecting latent tuberculosis (TB) infection, Mycobacterium tuberculosis-specific interferon (IFN)-γ release assays do not perform satisfactorily in predicting the risk of active TB (ATB) development. It is crucial to identify new biomarkers with high predictive accuracy to identify individuals bearing a high risk of progression. Methods: This was a sub-study of an open-label, randomized clinical trial for prevention of TB in silicosis patients. Twenty-six participants were diagnosed with ATB within 37-month’ follow-up. They were defined as TB progressors and matched in a 1:2 ratio with 52 TB nonprogressors. Results: We analyzed expression of 45 cytokines in QuantiFERON supernatants from TB progressors and nonprogressors, and granulocyte–macrophage colony-stimulating factor, vascular endothelial growth factor, interleukin (IL)-3, IFN-γ-induced protein 10, IL-10, and IL-9 outperformed IFN-γ as predictive markers. Conclusion: These findings highlight the potential of new biomarkers in identifying individuals with high risk of TB to undergo early intervention.Trial registration: ClinicalTrials.gov number: NCT02430259. |
|---|---|
| ISSN: | 1201-9712 |